DBL Potassium Dihydrogen Phosphate Drug Interactions

Angiotensin converting enzyme (ACE) inhibitors: Concurrent use with DBL Potassium Dihydrogen Phosphate Concentrated Injection may result in hyperkalaemia, especially in patients with renal impairment.
Calcium containing medicines: Concurrent use of DBL Potassium Dihydrogen Phosphate Concentrated Injection and calcium containing medicines may increase the risk of deposition of calcium in soft tissues.
Digitalis glycosides: The administration of DBL Potassium Dihydrogen Phosphate Concentrated Injection in digitalised patients with severe or complete heart block may result in hyperkalaemia.
Diuretics, potassium sparing: Concurrent use with DBL Potassium Dihydrogen Phosphate Concentrated Injection may result in hyperkalaemia, especially in patients with renal impairment.
Non-steroidal anti-inflammatory agents (NSAIDs): Concurrent use with DBL Potassium Dihydrogen Phosphate Concentrated Injection may result in hyperkalaemia, especially in patients with renal impairment.
Other phosphate containing medicines: Concurrent use with DBL Potassium Dihydrogen Phosphate Concentrated Injection may result in hyperphosphataemia, especially in patients with impaired renal function.
Potassium containing medicines: Concurrent use with DBL Potassium Dihydrogen Phosphate Concentrated Injection may result in hyperkalaemia, especially in patients with renal impairment.
Salicylates: Concurrent use with DBL Potassium Dihydrogen Phosphate Concentrated Injection may increase the serum concentration of salicylates, since salicylate excretion is decreased in acidified urine. This may result in toxic salicylate concentrations when phosphate is administered to patients already stabilized on salicylates.